AstraZeneca Exanta NDA Filing Set For 2003; Cost-Effective Vs. Warfarin?
AstraZeneca intends to position its anticoagulant Exanta (ximelagatran) as a cost-effective alternative to warfarin in the antithrombotic market
AstraZeneca intends to position its anticoagulant Exanta (ximelagatran) as a cost-effective alternative to warfarin in the antithrombotic market